Kalaris Therapeutics (KLRS) risk factors, FY2025 10-K

What changed since the prior 10-K

New

• NewRisks Related to Our Financial Position and Need for Additional Capital

  Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability

  Expenses may exceed expectations if regulatory authorities require additional trials or manufacturing arrangements for TH103 are delayed.

• NewRisks Related to Our Financial Position and Need for Additional Capital

  there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim

  We have never generated product revenue and expect to incur substantial additional expenditures to develop TH103 and expand into other indications.

• NewRisks Related to Our Financial Position and Need for Additional Capital

  We have never generated revenue from product sales and may never achieve or maintain profitability

  Clinical development of lead candidate TH103 began in June 2024, and achieving profitability requires successful commercialization.

• NewRisks Related to Our Financial Position and Need for Additional Capital

  achieving market acceptance of products for which we may obtain marketing approval as viable treatment options

  We are heavily dependent on TH103 and face severe operational risks if it fails to receive marketing approval or achieve market acceptance.

• NewRisks Related to Our Financial Position and Need for Additional Capital

  We have identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future or fail to maintain an effective system of internal control over financial reporting, which may result in material misstatements of our financial statements

  We identified material weaknesses in our internal control over financial reporting as of December 31, 2024, which remain unremediated.

• NewRisks Related to Our Financial Position and Need for Additional Capital

  Our ability to use our net operating loss carryforwards (“NOLs”) and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations

  As of December 31, 2025, federal and state net operating loss carryforwards were $83.9 million and $27.4 million, subject to Section 382 limitations.

• NewRisks Related to Research and Development of Our Product Candidates

  We are early in our development efforts. If we are unable to commercialize TH103 or any product candidate we may develop or experience significant delays in doing so, our business will be materially harmed

  We received IND clearance for TH103 in nAMD in June 2024 and reported initial Phase 1a SAD trial data in December 2025.

• NewRisks Related to Research and Development of Our Product Candidates

  maintaining a continued acceptable safety profile of our products following receipt of any marketing approvals

  Drug development involves high failure rates, and we must maintain an acceptable safety profile following any marketing approvals.

• NewRisks Related to Research and Development of Our Product Candidates

  business interruptions resulting from any health epidemics, pandemics or other contagious outbreaks may result in adverse effects on our business and operations

  Health epidemics or pandemics could adversely affect our business operations and cause unplanned clinical trial costs or delays.

• NewRisks Related to Research and Development of Our Product Candidates

  have the product removed from the market after obtaining marketing approval

  Significant preclinical or clinical trial delays could shorten commercial exclusivity periods or allow competitors to bring products to market first.

• NewRisks Related to Research and Development of Our Product Candidates

  We may conduct clinical trials at sites outside the United States. The Food and Drug Administration (the “FDA”) may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense

  The FDA may not accept foreign clinical trial data unless specific conditions regarding US population applicability and Good Clinical Practices are met.

• NewRisks Related to Research and Development of Our Product Candidates

  The results of early-stage clinical trials and preclinical studies may not be predictive of future results. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials

  Small patient numbers in early trials like the Phase 1b/2 clinical trial of TH103 may make results less predictive of later trial outcomes.

• NewRisks Related to Research and Development of Our Product Candidates

  If we experience delays or difficulties in the enrollment of patients in our clinical trials for TH103 or any other product candidate we develop, our receipt of necessary marketing approvals could be delayed or prevented

• NewRisks Related to Research and Development of Our Product Candidates

  the impact of any health epidemics, pandemics or other contagious outbreaks

• NewRisks Related to Research and Development of Our Product Candidates

  If dose limiting toxicities, serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of TH103 or any other product candidate we may develop, we may need to abandon or limit our further clinical development of those product candidates

• NewRisks Related to Research and Development of Our Product Candidates

  If TH103 or any other product candidate we may develop receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised

• NewRisks Related to Research and Development of Our Product Candidates

  harm to our reputation and resulting harm to physician or patient acceptance of our products

• NewRisks Related to Research and Development of Our Product Candidates

  We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success

• NewRisks Related to the Commercialization of Our Product Candidates

  any restrictions on the use of our products, if approved, together with other medications

• NewRisks Related to the Commercialization of Our Product Candidates

  unforeseen costs and expenses associated with creating an independent sales and marketing organization

• NewRisks Related to the Commercialization of Our Product Candidates

  Technology in the biopharmaceutical industry has undergone rapid and significant change, and we expect that it will continue to do so. Any products or processes that we develop may become obsolete or uneconomical before we recover any expenses incurred in connection with their development

• NewRisks Related to the Commercialization of Our Product Candidates

  the inability to commercialize any products that we may develop

• NewRisks Related to Our Dependence on Third Parties

  Manufacturing biologics is complex, and we may experience manufacturing problems that result in delays in our development or future commercialization programs

• NewRisks Related to Our Dependence on Third Parties

  the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us

• NewRisks Related to Our Dependence on Third Parties

  We currently rely, and may in the future rely, on single-source suppliers for certain materials and components used in the manufacturing of our product candidates

• NewRisks Related to Our Dependence on Third Parties

  We may enter into collaborations with third parties for the research, development and commercialization of certain of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates and our business could be adversely affected

• NewRisks Related to Our Dependence on Third Parties

  from these arrangements will depend on our collaborators’ abilities and efforts to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into

• NewRisks Related to Our Dependence on Third Parties

  We may seek to establish additional collaborations. If we are not able to establish or maintain additional collaborations, on commercially reasonable terms, we may have to alter our development and commercialization plans and our business could be adversely affected

• NewRisks Related to Our Dependence on Third Parties

  Any acquisitions or in-license transactions that we complete could disrupt our business, cause dilution to our stockholders or reduce our financial resources

• NewRisks Related to Our Intellectual Property

  countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop and market competing products

• NewRisks Related to Our Intellectual Property

  Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time

• NewRisks Related to Our Intellectual Property

  We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products

• NewRisks Related to Our Intellectual Property

  We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization of our current and any future product candidates

• NewRisks Related to Our Intellectual Property

  Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties

• NewRisks Related to Our Intellectual Property

  Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize TH103 and our other current or future product candidates in all of our expected significant foreign markets

• NewRisks Related to Our Intellectual Property

  If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed

• NewRisks Related to Our Intellectual Property

  Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations

• NewRisks Related to Our Intellectual Property

  Intellectual property rights do not necessarily address all potential threats to our competitive advantage

• NewRisks Related to Our Intellectual Property

  If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates

• NewRisks Related to Our Intellectual Property

  In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities

• NewRisks Related to Our Intellectual Property

  We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties

• NewRisks Related to Regulatory and Legal Compliance Matters

  Even if we complete the necessary preclinical studies and clinical trials for our product candidates, the regulatory approval process is expensive, time-consuming and uncertain and we may not receive approvals for the commercialization of some or all of our product candidates in a timely manner, or at all

• NewRisks Related to Regulatory and Legal Compliance Matters

  a product may not be approved for the indications that we request or may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable

• NewRisks Related to Regulatory and Legal Compliance Matters

  Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of its medicines that are approved for marketing in such jurisdiction will be subject to risk associated with foreign operations

• NewRisks Related to Regulatory and Legal Compliance Matters

  impose restrictions on operations, including costly new manufacturing requirements

• NewRisks Related to Regulatory and Legal Compliance Matters

  The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found or alleged to have improperly promoted off-label uses, it may become subject to significant liability

• NewRisks Related to Regulatory and Legal Compliance Matters

  If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway

• NewRisks Related to Regulatory and Legal Compliance Matters

  Recently enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates, if approved, and affect the prices we may obtain

• NewRisks Related to Regulatory and Legal Compliance Matters

  The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when approved

• NewRisks Related to Regulatory and Legal Compliance Matters

  Changes in and uncertainty surrounding U.S. and internal trade policy could have a material adverse impact on our business, financial condition and results of operations

• NewRisks Related to Employee Matters and Managing Growth

  Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel

• NewRisks Related to Employee Matters and Managing Growth

  We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations

• NewRisks Related to Employee Matters and Managing Growth

  improving our operational, financial and management controls, reporting systems and procedures

• NewRisks Related to the Ownership of Our Common Stock

  The market price of our common stock has been and is expected to continue to be volatile

• NewRisks Related to the Ownership of Our Common Stock

  general economic, industry and market conditions, such as those caused by the ongoing conflict between Russia and Ukraine, conflicts in the Middle East, inflation, fluctuations in interest rates and tariffs and other trade restrictions

• NewRisks Related to the Ownership of Our Common Stock

  We incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies

• NewRisks Related to the Ownership of Our Common Stock

  We are a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. We would cease to be a smaller reporting company if we have a public float in excess of $250 million or have annual revenues in excess of $100 million and a public float in excess of $700 million, determined on an annual basis

• NewRisks Related to the Ownership of Our Common Stock

  If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline

• NewRisks Related to the Ownership of Our Common Stock

  Our executive officers, directors and principal stockholder, Samsara LP, have the ability to control or significantly influence all matters submitted to our stockholders for approval

• NewRisks Related to the Ownership of Our Common Stock

  Samsara LP, our principal stockholder, beneficially owns greater than 50% of our outstanding shares of capital stock, which has caused us to be deemed a “controlled company” under the rules of Nasdaq

• NewRisks Related to the Ownership of Our Common Stock

  the compensation committee be composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibility

• NewRisks Related to the Ownership of Our Common Stock

  If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline

• NewRisks Related to the Ownership of Our Common Stock

  We have broad discretion in the use of our cash and cash equivalents and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment

• NewRisks Related to the Ownership of Our Common Stock

  Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition

Dropped

• DroppedRisks Related to the Merger

  The exchange ratio set forth in the merger agreement is not adjustable based on the market price of AlloVir’s common stock, so the merger consideration at the closing of the merger may have a greater or lesser value than at the time the merger agreement was signed

  Merger exchange ratio and AlloVir net cash adjustments.

• DroppedRisks Related to the Merger

  Failure to complete the merger may result in either Kalaris or AlloVir paying a termination fee to the other party, and could harm AlloVir’s common stock price and future business and operations of each company

  Merger termination fees of $3.48 million or $10.41 million.

• DroppedRisks Related to the Merger

  substantial costs related to the merger may be incurred by either party, such as financial advisor, legal and accounting fees, a majority of which must be paid even if the merger is not completed

  Substantial merger-related financial advisor, legal, and accounting costs.

• DroppedRisks Related to the Merger

  If the conditions to the merger are not satisfied or waived, the merger may not occur

  Conditions required to satisfy or waive the merger.

• DroppedRisks Related to the Merger

  The merger may be completed even though certain events occur prior to the closing of the merger that materially and adversely affect AlloVir or Kalaris

  Material adverse effects occurring prior to the merger closing.

• DroppedRisks Related to the Merger

  any specific action taken (or omitted to be taken) by AlloVir or Kalaris, as applicable, at or with the express written consent of the other party (which shall include any action taken (or omitted to be taken) that is expressly required to be taken by the merger agreement)

  Specific actions taken by AlloVir or Kalaris during the merger.

• DroppedRisks Related to the Merger

  AlloVir’s disposal of its historical assets and operations in connection with the proposed merger with Kalaris has made AlloVir a shell company. As a result, AlloVir is subject to more stringent reporting requirements, offering limitations and resale restrictions

• DroppedRisks Related to the Merger

  AlloVir’s directors and executive officers and those of Kalaris may have interests in the merger that are different from, or in addition to, the interests of AlloVir’s other stockholders generally

  AlloVir shell company reporting requirements and resale restrictions.

• DroppedRisks Related to the Merger

  compensated as non-employee directors of the combined company pursuant to the combined company’s non-employee director compensation policy that is expected to become effectives as of the closing of the merger

  Different interests of AlloVir and Kalaris directors and executive officers.

• DroppedRisks Related to the Merger

  AlloVir’s stockholders and Kalaris’ stockholders may not realize a benefit from the merger commensurate with the ownership dilution they will experience in connection with the merger

  Non-employee director compensation policy of the combined company.

• DroppedRisks Related to the Merger

  If the merger is not completed, AlloVir’s stock price may decline significantly

  Stockholder ownership dilution resulting from the merger.

• DroppedRisks Related to the Merger

  period-to-period fluctuations in financial results

  AlloVir stock price decline risks if the merger is not completed.

• DroppedRisks Related to the Merger

  The market price of the combined company’s common stock following the merger may decline as a result of the merger

  Period-to-period financial results fluctuations and securities litigation.

• DroppedRisks Related to the Merger

  the combined company does not achieve the perceived benefits of the merger as rapidly or to the extent anticipated by financial or industry analysts

• DroppedRisks Related to the Merger

  During the pendency of the merger, AlloVir and Kalaris may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the merger agreement, which could adversely affect their respective business prospects

• DroppedRisks Related to the Merger

  Certain provisions of the merger agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the merger agreement

• DroppedRisks Related to the Merger

  Because the lack of a public market for Kalaris’ capital stock makes it difficult to evaluate the fair market value of Kalaris’ capital stock, the value of the AlloVir’s common stock to be issued to Kalaris stockholders may be more or less than the fair market value of Kalaris’ capital stock

• DroppedRisks Related to the Merger

  Stockholder litigation could prevent or delay the consummation of the merger or otherwise negatively impact AlloVir’s, Kalaris’ or the combined company’s business, operating results and conditions

• DroppedRisks Related to the Merger

  AlloVir’s ability to consummate the merger depends on AlloVir’s ability to retain the employees required to consummate such transaction

• DroppedRisks Related to AlloVir

  AlloVir may not be successful in consummating the merger

• DroppedRisks Related to AlloVir

  Although there can be no assurance that the merger will be completed, the negotiation and consummation of the merger will require significant time on the part of AlloVir’s management, and the diversion of management’s attention may disrupt AlloVir’s business

• DroppedRisks Related to AlloVir

  Any of the foregoing risks could have a material adverse effect on AlloVir’s business, financial condition and prospects

• DroppedRisks Related to AlloVir

  AlloVir’s cash preservation activities, including the workforce reduction plan, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt AlloVir’s business

• DroppedRisks Related to AlloVir

  AlloVir may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm AlloVir’s business, and insurance coverage may not be sufficient to cover all costs and damages

• DroppedRisks Related to Capital Needs

  the ongoing costs of operating as a public company

• DroppedRisks Related to Sales, Marketing and Competition

  The occurrence of any event or penalty described above may inhibit AlloVir’s ability to successfully commercialize its products

• DroppedRisks Related to Business Development and Commercialization

  AlloVir may not successfully identify, acquire, develop or commercialize new potential product candidates

• DroppedRisks Related to Business Development and Commercialization

  AlloVir’s commercial success depends upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and the medical community, including hospitals and outpatient clinics

• DroppedRisks Related to Business Development and Commercialization

  Even if AlloVir is able to commercialize its product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which it seeks to commercialize its products, which could harm its business

• DroppedRisks Related to Business Development and Commercialization

  AlloVir obtains regulatory approval, and ultimately its ability to successfully commercialize any product candidate for which it obtains regulatory approval

• DroppedRisks Related to Business Development and Commercialization

  AlloVir must complete clinical testing before it can seek regulatory approval and begin commercialization of any of its product candidates

• DroppedRisks Related to Business Development and Commercialization

  Current and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for AlloVir to obtain regulatory approval of and commercialize its product candidates and affect the prices it may obtain

• DroppedRisks Related to Business Development and Commercialization

  enacted and future legislation please see “AlloVir’s Business—Government Regulation—Healthcare Reform” in this Annual Report on Form 10-K

• DroppedRisks Related to Business Development and Commercialization

  the availability of capital

• DroppedRisks Related to Business Development and Commercialization

  Price controls may be imposed in foreign markets, which may adversely affect AlloVir’s future profitability

• DroppedRisks Related to Business Development and Commercialization

  AlloVir expects the product candidates it develops will be regulated biologics and therefore they may be subject to competition sooner than anticipated

• DroppedRisks Related to Business Development and Commercialization

  AlloVir’s relationships with customers, third-party payors, physicians and healthcare providers will be subject to applicable anti-kickback, fraud and abuse, and other laws and regulations, which could expose it to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits

• DroppedRisks Related to Business Development and Commercialization

  Changes in and failures to comply with U.S. federal and state and foreign privacy and data protection laws, regulations and standards may adversely affect AlloVir’s business, operations and financial performance

• DroppedRisks Related to Business Development and Commercialization

  Artificial intelligence presents risks and challenges that can impact AlloVir’s business including by posing security risks to its confidential information, proprietary information, and personal data

• DroppedRisks Related to Business Development and Commercialization

  Certain of AlloVir’s directors and officers may have actual or potential conflicts of interest because of their positions with ElevateBio

• DroppedRisks Related to Business Development and Commercialization

  Should AlloVir resume development of its product candidates, it may need to grow the size of its organization, and it may experience difficulties in managing this growth

• DroppedRisks Related to Business Development and Commercialization

  expanding AlloVir’s facilities

• DroppedRisks Related to Business Development and Commercialization

  AlloVir’s employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for it and harm its reputation

• DroppedRisks Related to AlloVir’s Business

  Business disruptions could seriously harm AlloVir’s future revenue and financial condition and increase its costs and expenses

• DroppedRisks Related to AlloVir’s Business

  Changes in U.S. or foreign tax law or changes in AlloVir’s effective tax rates could adversely affect its business and financial condition

• DroppedRisks Related to AlloVir’s Business

  AlloVir’s ability to use its net operating loss carryforwards and other tax attributes may be limited

• DroppedRisks Related to AlloVir’s Business

  Unstable market, economic or geopolitical conditions may have serious adverse consequences on AlloVir’s business, financial condition and stock price

• DroppedRisks Related to AlloVir’s Business

  Furthermore, AlloVir’s stock price may decline due in part to the volatility of the stock market and the general economic downturn

• DroppedRisks Related to AlloVir’s Intellectual Property if the Merger is not Completed

  The patentability of inventions and the validity, enforceability and scope of patents in the biotechnology field is highly uncertain because it involves complex legal, scientific and factual considerations, and it has in recent years been the subject of significant litigation

• DroppedRisks Related to AlloVir’s Intellectual Property if the Merger is not Completed

  any of its partners are forced to grant a license to third parties under patents relevant to its business, or if it or its partners are prevented from enforcing patent rights against third parties, its competitive position may be substantially impaired in such jurisdictions

• DroppedRisks Related to AlloVir’s Intellectual Property if the Merger is not Completed

  AlloVir has in-licensed a significant portion of its intellectual property from its partners, including BCM. If AlloVir breaches any of its license agreements with these partners, it could lose the ability to continue the development and potential commercialization of one or more of its product candidates

• DroppedRisks Related to AlloVir’s Intellectual Property if the Merger is not Completed

  If AlloVir is unable to protect the confidentiality of its trade secrets and other proprietary information, the value of its technology could be materially adversely affected and its business could be harmed

• DroppedRisks Related to AlloVir’s Intellectual Property if the Merger is not Completed

  information could enable competitors to quickly duplicate or surpass its technological achievements, including by enabling them to develop and commercialize products substantially similar to or competitive with its product candidates, thus eroding its competitive position in the market

• DroppedRisks Related to AlloVir’s Dependence on Third Parties if the Merger is Not Completed

  AlloVir depends substantially on intellectual property licensed from third parties, including BCM, and termination of any of these licenses could result in the loss of significant rights, which would harm its business

• DroppedRisks Related to AlloVir’s Dependence on Third Parties if the Merger is Not Completed

  the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by its licensors and it and its partners

• DroppedRisks Related to AlloVir’s Dependence on Third Parties if the Merger is Not Completed

  AlloVir may not realize the benefits of strategic alliances that it may form in the future or of potential future product acquisitions or licenses

• DroppedRisks Related to Clinical Development

  maintaining and growing an organization of scientists and functional experts who can develop and commercialize its products and technology

• DroppedRisks Related to Clinical Development

  with substantial evidence gathered in preclinical studies and clinical trials, that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate with respect to such product candidate to assure safety, purity and potency

• DroppedRisks Related to Clinical Development

  its failure to obtain and retain accurate data in its clinical trials

• DroppedRisks Related to the Industry

  developing therapies for types of diseases beyond those initially addressed by its current product candidates

• DroppedRisks Related to the Industry

  AlloVir cannot be sure that the manufacturing processes used in connection with its T cell immunotherapy product candidates will yield a sufficient supply of satisfactory products that are safe, pure and potent, comparable to those T cells produced by its partners historically, scalable or profitable

• DroppedRisks Related to the Industry

  Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for AlloVir’s product candidates would substantially harm its business

• DroppedRisks Related to the Industry

  changes in governmental regulations or administrative actions, failure by it or third parties to comply with regulatory requirements, or lack of adequate funding to continue a clinical trial

• DroppedRisks Related to the Industry

  clinicians’ and patients’ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new product candidates that may be approved for the indications AlloVir is investigating

• DroppedRisks Related to the Industry

  AlloVir currently relies on CROs, other vendors and clinical trial sites to ensure the proper and timely conduct of its clinical trials, and while AlloVir has agreements governing their committed activities, AlloVir has limited influence over their actual performance

• DroppedRisks Related to the Industry

  experience damage to its reputation

• DroppedRisks Related to the Industry

  Should AlloVir resume development of its product candidates, it may not be able to obtain or maintain orphan drug designation to its product candidates, or to obtain and maintain the benefits associated with orphan drug designation, including the potential for market exclusivity

• DroppedRisks Related to the Industry

  the first applicant cannot supply enough orphan medicinal product

• DroppedRisks Related to Litigation if the Merger is Not Completed

  AlloVir may be at an increased risk of securities class action litigation

• DroppedRisks Related to Litigation if the Merger is Not Completed

  a decline in AlloVir’s share price

• DroppedRisks Related to Intellectual Property Litigation

  If AlloVir is sued for infringing the intellectual property rights of third parties, the resulting litigation could be costly and time-consuming and could prevent or delay its development and commercialization efforts

• DroppedRisks Related to Intellectual Property Litigation

  AlloVir may face claims that it misappropriated the confidential information or trade secrets of a third party. If AlloVir is found to have misappropriated a third party’s trade secrets, it may be prevented from further using these trade secrets, which could limit its ability to develop its product candidates

• DroppedRisks Related to Intellectual Property Litigation

  AlloVir may become involved in lawsuits to protect or enforce its intellectual property, which could be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of its business

• DroppedRisks Related to Intellectual Property Litigation

  using the technology at issue on the grounds that its patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of AlloVir’s patents at risk of being invalidated, held unenforceable or interpreted narrowly

• DroppedRisks Related to Manufacturing if the Merger is Not Completed

  ongoing compliance with cGMP regulations and other requirements of the FDA, EMA or other comparable regulatory agencies

• DroppedRisks Related to Manufacturing if the Merger is Not Completed

  Developing advanced manufacturing techniques and process controls is required to fully utilize AlloVir or its partner’s facility. Without further investment, advances in manufacturing techniques may render AlloVir or its partner’s facility and equipment inadequate or obsolete

• DroppedRisks Related to Third Party Manufacturing

  AlloVir and its third-party partners are subject to a multitude of manufacturing risks, any of which could substantially increase its costs and limit supply of its product candidates

• DroppedRisks Related to Third Party Manufacturing

  Concurrently with the license of AlloVir’s existing product candidates, it acquired manufacturing process know-how and, in some cases, inventory of process intermediates and clinical materials from its partners

• DroppedRisks Related to Third Party Manufacturing

  Maintaining clinical and commercial timelines is dependent on AlloVir’s end-to-end supply chain network to support manufacturing; if it experiences problems with its third party suppliers, the development and potential commercialization of its product candidates may be delayed

• DroppedRisks Related to Third Party Manufacturing

  If AlloVir is not able to successfully transfer and produce comparable product candidates, its ability to further develop and manufacture its product candidates may be negatively impacted

• DroppedRisks Related to Third Party Manufacturing

  AlloVir is dependent on a limited number of suppliers and, in some instances, a sole supplier, for some of its components and materials used in its product candidates

• DroppedRisks Related to Third Party Manufacturing

  fluctuation in delivery by its suppliers due to changes in demand from it or their other customers

• DroppedRisks Related to Third Party Manufacturing

  If AlloVir and its third-party manufacturers fail to comply with environmental, health and safety laws and regulations, AlloVir could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business

• DroppedRisks Related to Third Party Manufacturing

  If AlloVir’s sole raw material suppliers, clinical or commercial drug product manufacturing facility is damaged or destroyed or production at these facilities is otherwise interrupted, its business would be negatively affected

• DroppedRisks Related to Third Party Manufacturing

  The trading price of AlloVir’s common stock may be volatile

• DroppedRisks Related to Third Party Manufacturing

  other events or factors, many of which are beyond AlloVir’s control

• DroppedRisks Related to Third Party Manufacturing

  In accordance with Nasdaq Listing Rule 5810(c)(3)(A), AlloVir has been provided an initial period of 180 calendar days, or until August 7, 2024 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement

• DroppedRisks Related to Third Party Manufacturing

  On February 4, 2025, AlloVir received a letter from the Staff, notifying it that, for the last 11 consecutive business days, its common stock had maintained the Minimum Bid Price Requirement and accordingly regained compliance with Listing Rule 5450(a)(1) and this matter is now closed

• DroppedRisks Related to Third Party Manufacturing

  AlloVir’s principal stockholders and management own a significant percentage of its stock and will be able to exert significant influence over matters subject to stockholder approval

• DroppedRisks Related to Third Party Manufacturing

  Raising additional capital may cause dilution to AlloVir’s existing stockholders, restrict its operations or require it to relinquish rights to its product candidates on terms that are unfavorable to it

• DroppedRisks Related to Third Party Manufacturing

  AlloVir does not intend to pay dividends on its common stock, so any returns will be limited to the value of its stock

• DroppedRisks Related to Third Party Manufacturing

  AlloVir is an emerging growth company and a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make its common stock less attractive to investors

• DroppedRisks Related to Third Party Manufacturing

  which requires the market value of its common stock that is held by non-affiliates to exceed $700 million as of the prior June 30th, and (2) the date on which it has issued more than $1 billion in non-convertible debt during the prior three-year period

• DroppedRisks Related to Third Party Manufacturing

  AlloVir incurs significant increased costs as a result of operating as a public company, and its management is required to devote substantial time to new compliance initiatives

• DroppedRisks Related to Third Party Manufacturing

  Sales of a substantial number of shares of AlloVir’s common stock by its existing stockholders in the public market could cause its stock price to fall

• DroppedRisks Related to Third Party Manufacturing

  AlloVir has broad discretion over the use of its cash and cash equivalents and may not use them effectively

• DroppedRisks Related to Third Party Manufacturing

  If AlloVir fails to establish and maintain proper and effective internal control over financial reporting, its operating results and its ability to operate its business could be harmed

• DroppedRisks Related to Third Party Manufacturing

  AlloVir’s business, its stock price and trading volume could decline

Reworded

• 100% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

  the extent to which we in-license or acquire additional technologies or product candidates

  Updated cash runway to December 31, 2025, showing $118.0 million funding operations into the fourth quarter of 2027.

  Was: acquires or in-license other product candidates and technologies

• 99% rewrittenRisks Related to the Commercialization of Our Product Candidates

  If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if and when they are approved

  Added specific plan to commercialize TH103 using our own specialty salesforce rather than general third-party arrangements.

  Was: If AlloVir is unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell its product candidates, it may be unable to generate any revenue

• 98% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

  We will need substantial additional funding for our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts

  Added specific reference to ongoing clinical trials and pre-clinical activities for TH103 driving future expense increases.

  Was: AlloVir will need substantial additional funding, and if it is unable to raise capital when needed, it could be forced to delay, reduce or eliminate its product discovery and development programs or commercialization efforts

• 98% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

  We have incurred significant losses since our inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future, and may never achieve or maintain profitability

  Added specific accumulated deficit of $160.0 million and net losses of $43.4 million for 2025 and $69.2 million for 2024.

  Was: AlloVir is a clinical-stage cell therapy company and it has incurred net losses since its inception. AlloVir anticipates that it will continue to incur significant losses for the foreseeable future, and may never achieve or maintain profitability

• 97% rewrittenRisks Related to the Commercialization of Our Product Candidates

  We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of the market for our products

  Narrowed competitive focus specifically to the biopharmaceutical market for retinal diseases and ophthalmology.

  Was: AlloVir faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than it does

• 95% rewrittenRisks Related to Employee Matters and Managing Growth

  Our internal computer systems, or those of our collaborators, vendors, suppliers, contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs

  Expanded cybersecurity risks to highlight increasing frequency, sophistication, and intensity of malicious cyber-attacks.

  Was: AlloVir’s internal computer systems, or those used by its third-party CROs or other contractors or consultants, may fail or suffer from cybersecurity incidents or breaches, which could result in a material disruption of the development programs of its product candidates

• 95% rewrittenRisks Related to Research and Development of Our Product Candidates

  Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data becomes available and are subject to audit and verification procedures, which could result in material changes in the final data

  Added specific risks regarding clinical trial interim results being subject to audit and verification procedures.

  Was: Interim, “topline” or preliminary data from AlloVir’s clinical trials that it may announce or share with regulatory authorities from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data

• 95% rewrittenRisks Related to Our Intellectual Property

  Changes in United States patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products

  Updated patent law risk to emphasize specific reliance on intellectual property protecting TH103.

  Was: Changes in U.S. or foreign patent laws could diminish the value of patents in general, thereby impairing AlloVir’s ability to protect its products

• 89% rewrittenRisks Related to Our Intellectual Property

  We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property

  Was: AlloVir may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that its employees have wrongfully used or disclosed alleged trade secrets of their former employers

• 89% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

  Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability

  Was: AlloVir has a limited operating history, which may make it difficult to evaluate the success of its business to date and to assess its future viability

• 89% rewrittenRisks Related to the Commercialization of Our Product Candidates

  Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop

  Was: Product liability lawsuits against AlloVir could cause it to incur substantial liabilities and to limit commercialization of any products that it may develop

• 87% rewrittenRisks Related to the Ownership of Our Common Stock

  Transfers of our securities utilizing Rule 144 of the Securities Act may be limited

  Was: Transfers of the combined company’s securities utilizing Rule 144 of the Securities Act may be limited

• 85% rewrittenRisks Related to Our Intellectual Property

  If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected

  Was: If AlloVir’s trademarks and trade names are not adequately protected, then it may not be able to build name recognition in its markets of interest and its business may be adversely affected

• 84% rewrittenRisks Related to Our Financial Position and Need for Additional Capital

  Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates

  Was: Raising additional capital may cause dilution to the combined company’s stockholders, restrict its operations or require it to relinquish rights to its technologies or product candidates

• 81% rewrittenRisks Related to Our Intellectual Property

  We may not be able to protect our intellectual property rights throughout the world, which could impair our business

  Was: AlloVir may not be able to protect its intellectual property rights throughout the world

• 79% rewrittenRisks Related to Our Intellectual Property

  Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements

  Was: Obtaining and maintaining AlloVir’s patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and its patent protection could be reduced or eliminated for non-compliance with these requirements

• 73% rewrittenRisks Related to the Ownership of Our Common Stock

  Pursuant to the 2020 Plan and the 2019 Plan, our management is authorized to grant stock options to our employees, directors, and consultants

  Was: Pursuant to the 2020 plan, its management is authorized to grant stock options to its employees, directors, and consultants

• 64% rewrittenRisks Related to the Ownership of Our Common Stock

  We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be difficult for our stockholders to sell shares of our common stock

  Was: AlloVir does not know whether an active, liquid and orderly trading market will develop for its common stock or what the market price of its common stock will be and, as a result, it may be difficult for its stockholders to sell shares of its common stock

• 46% rewrittenRisks Related to the Ownership of Our Common Stock

  Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the 2020 Plan or the 2019 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall

  Was: Future sales and issuances of AlloVir’s common stock or rights to purchase common stock, including pursuant to the 2020 Stock Option and Grant Plan (the “2020 plan”), could result in additional dilution of the percentage ownership of its stockholders and could cause its stock price to fall

• 43% rewrittenRisks Related to the Ownership of Our Common Stock

  the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock

• 37% rewrittenRisks Related to the Ownership of Our Common Stock

  Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management

  Was: Anti-takeover provisions under AlloVir’s charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of its common stock and may prevent or frustrate attempts by its stockholders to replace or remove its current management

All 85 risk factors

Headings as the filing states them, in filing order.

Other Kalaris Therapeutics 10-Ks

• FY2024 10-K risk factors

  119 risks

  Kalaris faces high-risk merger dynamics with AlloVir, including valuation adjustments, termination fees, and stockholder dilution. The company is heavily dependent on future financing, regulatory approvals, and competitive pressures in the biotech sector. Clinical-stage development carries substantial risks of failure, trial delays, and uncertain market acceptance.

  Filed Mar 07, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.